Scipher Medicine Presents New Data at the European League Against Rheumatism (EULAR) 2021 Further Validating PrismRA® Test Molecular signature test predicts likelihood of non-response to adalimumab or etanercept, two of the world’s most expensive medications, in an independent validation cohort PrismRA demonstrates a more...

Scipher Applies Spectra™ Platform to Discover Drugs Targeting Autoimmune Patients Refractory to Existing Therapies - Leverages large genomic database from Scipher’s testing business.- Proven Spectra™ platform brings precision therapeutics to autoimmune diseases.- Program commercialized through pharma partnerships....

Scipher Medicine Announces $82 Million Financing -aMoon and Northpond Ventures led the round.-Additional investors include Echo Health Ventures, Khosla Ventures and Alumni Ventures.-Financing will support commercialization of precision medicine...

WellDyne Partners with Scipher Medicine to Improve Patient Outcomes and Lower Costs for Rheumatoid Arthritis Care WALTHAM, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Scipher Medicine, a precision immunology company matching patients with their most effective therapy, today announced a partnership with WellDyne, a...